A solution containing 0.05% Lipovenös ® appears clear to the eye and therefore it is perfectly possible that our centrifuged emulsions contained approximately 10 mg/dl triglycerides as suggested. Consequently, a part of a "direct lipid effect" may still be present even in the centrifuged emulsions. It should be noted, however, that Nadrowitz et al. used Lipofundin ® and Intralipid ® in their experiments, whereas we used Lipovenös ® . Even though Lipofundin ® and Lipovenös ® contain a similar mixture of triglycerides containing long-and medium-chain fatty acids, presently it is unclear whether the medium-/long-chain fatty acid mixture of Lipofundin ® or a different component (that may or may not be present also in Lipovenös ® ) is responsible for the inhibition of Nav1.5-mediated currents demonstrated by Nadrowitz et al. In this regard, it is interesting that although Lipofundin ® inhibited Nav1.5-mediated currents, Intralipid ® did not. It seems prudent to assume that this is due to differences in lipid content, however, at this point this is a speculation and warrants further exploration.
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In our article, to validate the results, we compared the apparent reduction of the bupivacaine concentration as assessed by concentration-response analysis of the patch clamp experiments to the actual reduction of the bupivacaine concentration as assessed by gas chromatographymass spectrometry. We found that both approaches yielded similar bupivacaine concentrations in the centrifuged lipid emulsions. Consequently, we do not expect that residual triglycerides have significantly affected our results.
Taken together, we do not think that the reasonable concerns raised by Hori et al. can explain the "direct lipid effect" as described in our article. Yet, we are grateful for their comment as it clearly points out that the nature of what we have called "direct lipid effect" in our article is, at present, unclear. In fact, it includes every effect that cannot be attributed to the lipid sink. Clearly, we cannot rule out that a part of this effect may be explained by limitations of our experimental approach, but most importantly, more experiments are necessary to explore the nature of this effect. We would like to add a few points:
1. Technology has been described as both part of the problem and part of the solution for safer health care. Healthcare providers can be so focused on data from monitors that they fail to detect potentially important subtle changes in clinical status. 2 If a clinician fails to prescribe a correct narcotic dose and fails to recognize a narcotic overdose, we think there is a lack of clinical acumen.
Use of high-end technology in simple clinical decisions
would be shunning our responsibility as physicians. 3. Problems may emerge based on the sheer volume and the complexity of new devices. 2 4. The race for providing healthcare technology is presently market driven dominated by a few multinational companies. There is no focus on making it inexpensive and widely available. 3 5. Automated patient care systems also face problems of system downtime and data accuracy which further spiral costs of health care. 4 6. We still have a long way to go till such technology becomes widely available, is used efficiently for patient safety, and becomes truly "productive." Correspondence (Accepted for publication July 2, 2014.) In Reply:
We thank Drs. Saluja and Kamdar for their comments on our recent editorial view entitled, "From Heroism to Safe Design: Leveraging Technology" which appeared in the March 2014 issue of ANESTHESIoLogY. 1 We agree that technology has been proposed as a healthcare solution and is also viewed as an impediment to clinical care by many. This dichotomy is typical of an under-engineered system in which technical capabilities exceed the cultural and workflow processes that use the technology. We are not suggesting that technical solutions should or even can replace clinical decision making and acumen. However, the example of narcotics overdose is often used to highlight failures of our current system. The responses of patients to narcotics are highly devices. However, this needs to be done via a joint effort of public policy and private industry. It is not enough for the medical device companies to merely share patient data with clinicians. We need the Food and Drug Administration (FDA) to promote an agreed-upon coding language and a set of "open protocols" for medical devices and electronic medical records before it grants FDA clearance. once a common coding language or standard emerges, medical devices and records will truly be able to speak to each other. We will then be able to experience realistic "plug-in-play" capabilities within our wards, our operating rooms, and our intensive care units and realize the possibilities of patient safety design that Pronovost et al. have kindled in our minds. Such a common standard will also lower the coding barriers for entry into this product market thus allowing entrepreneurial clinicians and researchers to create decision support and data management systems that can be widely integrated in less expensive ways into care across the country. As clinicians, we need to promote this movement by voting with our hospital dollars when we make device purchases and we need to lobby the FDA to promote interoperability with sound public policy regulations to help advocate for the ultimate safety of our patients.
